The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 28, 2023

Filed:

Aug. 20, 2020
Applicant:

Teva Pharmaceuticals Usa, Inc., North Wales, PA (US);

Inventors:

Vijay Joguparthi, Khammam, IN;

Rosario LoBrutto, Monroe, NY (US);

Assignee:

Teva Pharmaceuticals USA, Inc., North Wales, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/137 (2006.01); C09J 175/16 (2006.01); A61K 47/02 (2006.01); A61L 31/02 (2006.01); A61L 31/04 (2006.01); A61L 31/16 (2006.01); A61M 5/20 (2006.01); A61M 5/31 (2006.01); A61M 5/315 (2006.01); A61M 5/32 (2006.01); A61M 5/34 (2006.01); C09J 175/04 (2006.01); B65B 3/00 (2006.01); A61K 9/00 (2006.01); B65B 55/14 (2006.01); A61K 47/12 (2006.01);
U.S. Cl.
CPC ...
A61K 31/137 (2013.01); A61K 47/02 (2013.01); A61L 31/022 (2013.01); A61L 31/026 (2013.01); A61L 31/048 (2013.01); A61L 31/16 (2013.01); A61M 5/2033 (2013.01); A61M 5/3129 (2013.01); A61M 5/31591 (2013.01); A61M 5/3243 (2013.01); A61M 5/349 (2013.01); C09J 175/16 (2013.01); A61K 9/0019 (2013.01); A61K 47/12 (2013.01); A61M 5/329 (2013.01); A61M 2005/2026 (2013.01); A61M 2205/02 (2013.01); A61M 2207/00 (2013.01); B65B 3/003 (2013.01); B65B 55/14 (2013.01); C09J 175/04 (2013.01);
Abstract

The invention relates to a pre-filled syringe, an auto-injector device comprising such pre-filled syringe, a method of administering a pharmaceutical composition with such auto-injector device, and a manufacturing method for such auto-injector device. The pre-filled syringe comprises a container and a needle. The container is filled with a pharmaceutical composition comprising epinephrine, a buffer, and water. The buffer is configured to buffer in a pH range between 3 and 4. The needle is adhered to the container by means of a urethane acrylate or urethane methacrylate acrylic light cure adhesive, which is configured to provide a pull out resistance of the needle relative to the container which is between 30 N to 100 N, preferably between 50 N to 70 N, more preferably greater than 60 N after 90 days exposure to the pharmaceutical composition at 40° C. and 75% relative humidity (RH). In an example, the pharmaceutical composition is for the treatment of an anaphylactic event.


Find Patent Forward Citations

Loading…